Entera Bio Ltdis A Clinical Stage Biopharmaceutical Company Based In Jerusalemisraelfounded In 2010The Company Specializes In Developing Oral Peptide And Protein Replacement Therapies To Meet Significant Medical Needsparticularly Where Injectable Treatments Face Challenges Related To Costconvenienceand Patient Compliance Utilizing Its Proprietary N Tab Platformentera Bio Enhances The Stability And Absorption Of Peptides In The Gastrointestinal Tractallowing For Oral Delivery Of Large Molecules Typically Given By Injectionthe Company S Product Pipeline Includes Several Candidatessuch As Eb613 For Osteoporosiseb612 For Hypoparathyroidismand An Oral Formulation Of Oxyntomodulin For Obesity And Metabolic Disordersentera Bio Also Collaborates With Opko Biologicsincto Further Its Development Efforts In The Biopharmaceutical Field
